England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

Relapsing-remitting multiple sclerosis (MS) is commonly treated with parenteral drugs that can lead to adverse events and poor adherence. Three phase 3 randomized trials evaluated the efficacy and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...

A 49-year-old man with a long history of relapsing-remitting multiple sclerosis presents to the clinic for a routine follow-up visit. The patient was initially treated with glatiramer acetate ...

WEST PALM BEACH, Fla. -- The investigational oral Bruton's tyrosine kinase (BTK) inhibitor evobrutinib failed to distinguish itself from teriflunomide (Aubagio) in two phase III trials of relapsing ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...